Stay updated with breaking news from Serine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. (60/61 patients) as well as South Africa.
Researchers examined how SARS-CoV-2 variants of concern differentially use an additional metalloproteinase-dependent entry pathway to enter the host cells.
In a recent study posted to the Research Square* preprint server, which is under consideration at Scientific Reports, a team of researchers developed a novel human Alveolar Epithelial Lentivirus immortalized (hAELVi) cell infection model to estimate the replication potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses in the lower respiratory tract of humans.
The role played by the host enzyme TMPRSS2 in infection and cancer is the focus of a new study.
In a study posted to the bioRxiv* preprint server, a team of researchers from the United States evaluated the protective effect of the preclinical version of the current Moderna Omicron-targeted mRNA-1273.529 vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 Omicron infection in mice.